A Phase 1 interventional study of VSL#3 in Fatty Liver, sponsored by VSL Pharmaceuticals. Terminated at 1 site in United States. Open to participants aged 45 Years to 70 Years. Per ClinicalTrials.gov, last updated 2010-02-11.
Sponsored by VSL Pharmaceuticals · Phase 1, Interventional, and Treatment
Non-alcoholic fatty liver disease (NAFLD) is an accumulation of fat and fibrous tissue in the liver. It is the most common cause of chronic liver disease in the United States. The exact cause of NAFLD is unknown, but it is more common among people with conditions such as adult-onset diabetes. NAFLD can strike people of all ages but most often affects adults between the ages of 40 and 60. Research indicates that overgrowth of gut bacteria can start a chain of biological processes that stress the liver, causing liver inflammation. Probiotics, living bacteria taken orally, may decrease the stress on the liver by reducing this bacterial overgrowth and/or strengthening the gut walls. Because probiotics are generally safe, inexpensive, and easy to tolerate they are an attractive treatment option for NAFLD.
1,451 studies on the registry are indexed under Fatty Liver; 292 are open to participants now.
This study's planned enrollment of 30 is below the median of 60 across 1,003 interventional studies indexed under Fatty Liver.
Browse Fatty Liver studies →VSL Pharmaceuticals is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
MRI
Liver biopsy
Blood work
This study is terminated, as verified in Dec 2004. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
VSL Pharmaceuticals